A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Terminated; Phase 1

Conditions: Cancer

Treatments: Drug: Oral Taxane

Study type: Interventional

Funder types: Industry

Identifiers

NCT00332748

CA165-030

Details and patient eligibility

About

The purpose of this study is to determine what effects Esomeprazole (Nexium) has on increasing or decreasing the amount of oral taxane in the blood, and to determine the safety of oral taxane and effect of oral taxane on the cancer.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Advanced cancers excluding cancers within the blood
• Adequate kidney and liver function
• > = 4 weeks from last course of chemotherapy

Exclusion criteria

• Inability to swallow capsules
• Other active medical disorder
• Abnormal heart function or use of drugs that affect the heart

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)